منابع مشابه
Nebivolol in the treatment of chronic heart failure
Nebivolol is a highly selective beta1-adrenergic blocker that also enhances nitric oxide bioavailability via the L-arginine-nitric oxide pathway, leading to vasodilation and decreased peripheral vascular resistance. It is marketed in Europe for the treatment of hypertension and heart failure and is currently being reviewed for use in the US by the Food and Drug Administration. Nebivolol appears...
متن کاملEffect of Nebivolol on MIBG Parameters and Exercise in Heart Failure with Normal Ejection Fraction
BACKGROUND More than 50% of the patients with heart failure have normal ejection fraction (HFNEF). Iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy and cardiopulmonary exercise test (CPET) are prognostic markers in HFNEF. Nebivolol is a beta-blocker with vasodilating properties. OBJECTIVES To evaluate the impact of nebivolol therapy on CPET and123I-MIBG scintigraphic parameters in ...
متن کاملDiastolic heart failure in hypertension: possible preventive benefits of nebivolol beyond lowering blood pressure.
ABSTRACT Arterial hypertension is one of the most prevalent cardiovascular diseases and one of the most important causes of heart failure with low or preserved ejection fraction. Although many drugs are highly effective in lowering blood pressure, the optimal treatment for preventing progression to heart failure is still uncertain. Beta-blockers, a class of drugs with well-established indicatio...
متن کاملCarvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure
OBJECTIVE It is unclear whether carvedilol and nebivolol produce different effects on short-term left ventricle (LV) systolic function in heart failure (HF). These drugs could improve systolic and diastolic functions of the LV. Thus, we aimed to compare their effects on LV systolic functions in patients with non-ischemic HF. METHODS This study included 61 symptomatic non-ischemic HF patients ...
متن کاملNebivolol therapy improves QTc and QTcd parameters in heart failure patients
AIM It has previously been shown that β-blocker therapy reduces QT dynamics in heart failure patients. The aim of this study was to demonstrate this improvement with the third-generation β-blocker, nebivolol. METHODS A total of 72 heart failure patients with systolic dysfunction were included in the study. Corrected QT (QTc) and QT dispersion (QTcd) were measured manually by two independent o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Updates in Cardiology
سال: 2019
ISSN: 2619-9734
DOI: 10.5543/ucard.2019.33042